Dyadic International (NASDAQ:DYAI) Stock Passes Below 50-Day Moving Average – Time to Sell?

Dyadic International, Inc. (NASDAQ:DYAI) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.66 and traded as low as $1.52. Dyadic International shares last traded at $1.54, with a volume of 25,519 shares.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Dyadic International in a report on Thursday, November 14th.

Dyadic International Price Performance

The company has a market cap of $45.57 million, a PE ratio of -6.70 and a beta of 0.89. The business has a 50 day moving average of $1.66 and a 200 day moving average of $1.39. The company has a debt-to-equity ratio of 1.54, a current ratio of 5.15 and a quick ratio of 5.15.

Dyadic International (NASDAQ:DYAI) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.06. The firm had revenue of $1.96 million during the quarter, compared to analysts’ expectations of $1.05 million. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. During the same period last year, the company posted ($0.06) EPS. As a group, research analysts predict that Dyadic International, Inc. will post -0.18 EPS for the current year.

Institutional Trading of Dyadic International

An institutional investor recently raised its position in Dyadic International stock. Chapin Davis Inc. increased its position in Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 868,301 shares of the biotechnology company’s stock after purchasing an additional 21,000 shares during the quarter. Chapin Davis Inc. owned approximately 2.97% of Dyadic International worth $903,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.